ReviewDiagnostics (Basel, Switzerland)2026
Coronary Flow Velocity Reserve by Stress Echocardiography: The Prognostic Key of Multiple Heart Diseases.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although evaluating coronary flow velocity reserve (CFVR) via stress echocardiography (SE) has been available for over three decades, its integration into routine clinical practice remains underutilized globally despite substantial technical and conceptual advances. A diminished CFVR serves as a potent predictor of major adverse cardiovascular events (MACE) and all-cause mortality across a broad spectrum of cardiovascular diseases. Its prognostic value is particularly robust in epicardial coronary artery disease, heart failure, coronary microvascular dysfunction, nonischemic cardiomyopathies, metabolic disorders (e.g., diabetes mellitus and obesity), hypertrophic cardiomyopathy, systemic autoimmune diseases, and cardiac allograft vasculopathy. This comprehensive narrative review details the technical methodology for interrogating resting and stress-induced coronary flow velocity (CFV) under physical and pharmacological protocols. Furthermore, it highlights the clinical applicability of CFVR by synthesizing single-center observational insights with evidence from large-scale multicenter registries, advocating for its broader adoption into diagnostic workflows to refine risk stratification and guide therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.